PS
NBIX icon

Planning Strategies’s Neurocrine Biosciences NBIX Stock Holding History

Planning Strategies’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.52K Buy
+9
New +$1.33K ﹤0.01% 658

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Planning Strategies's NBIX Position: Q2 2026 in Review

Planning Strategies opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 9 shares worth $1.52K. The stake represents ﹤0.01% of the portfolio and ranks #658 among its holdings.

733 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Planning Strategies held 9 shares of Neurocrine Biosciences worth $1.52K as of Q2 2026.
  • Neurocrine Biosciences was a new Planning Strategies position in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Planning Strategies's portfolio in Q2 2026, its #658 holding.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Planning Strategies's 13F filing for Q2 2026, filed 27 Jul 2026.